68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a phase II clinical trial study to show how well the 68Ga-PSMA-11 (ProstaMedix™)
PET-CT scan works in detecting tumor location and size in patients with suspected or
confirmed prostate cancer, as well as prostate cancer that may have come back in patients
with elevated PSA ( a prostate-specific antigen tumor marker) after initial treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Ebrahim Delpassand
Collaborators:
Excel Diagnostics and Nuclear Oncology Center RadioMedix Radiomedix, Inc.